The Affordable Care Act’s primary objectives are to transform the current U.S. healthcare ecosystem into one that is:

1. good for patients, who can enjoy better health, share in their health decisions, and manage their expense effectively
2. good for the industry, leading to overall cost-effective healthcare
3. good for physicians and other healthcare professionals, enabling them to focus on delivery of optimal medical care
4. good for healthcare practices, aligning practitioners, fostering collaboration, and working toward a single goal of delivery of optimal care

If we were to rate the current progress of ACA, the healthcare sectors would have a lot going for them, but looking ahead, it may be a bumpy ride over the next few years with a lot more work required. As we benchmark the financial outlook for the first quarter of 2018, the positive indicators show healthcare companies’ bal

Long before the opioid epidemic was thought to be a public health emergency, prescription drug abuse and misuse were steadily increasing in the U.S. 

To combat this, states and hospitals have been building technological platforms to enable prescription drug monitoring programs that can the track habits of both prescribers and patients. But use of PDMPs varies by state, with some states mandating its use and others merely recommending that hospitals and medical groups opt-in. 

With the Trump administration saying it will crack down on opioid abuse, it begs the question: Could these data-heavy platforms make a dent in the crisis?

Every state but Missouri

As it stands, every state has its own PDMP, outside of Missouri -- the state has made multiple attem

Pharmacists, how many times have you seen a patient pay for more their medication than they should, all because you’re prohibited from telling them about ways to save money?

How often have you had to tell a patient that the cost for their chronic medication has gone up yet again? This probably happens multiple times a day, leaving you frustrated and reaching for your own antacid or pain reliever.

These situations are now being heard by legislators, who are introducing bills that will address some of the related activities behind these situations, including price increases by manufacturers and contract provisions that prevent pharmacists from sharing information about less expensive alternatives.

Many states are introducing legislation, often referred to as “The No Gag Rule on Pharmacists Act” that will prohibit health insurance companies and pharmacy benefits managers (PBMs) from contractually preventing pharmacists from telling their customers about cheaper ways